Combination targeting of both CD47 and PD-L1 resulted in synergistic inhibitory effect on tumor growth in the MPC-83 but not Panc02 syngeneic PDAC mouse model due to their differential effect on the key immune-activating genes and infiltrating immune cells in the TME. The gene discussed is CD47; the disease is neoplasm.